Posted by Michael Wonder on 30 Oct 2024
Osimertinib mesylate in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with advanced EGFR mutation positive non-small-cell lung cancer
30 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of osimertinib mesylate in combination with pemetrexed and platinum-based chemotherapy in the NHS in England.
For the time being, osimertinib mesylate, when used in combination with pemetrexed and platinum-based chemotherapy, is not recommended for the first-line treatment of adults with advanced non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
